Folate (B9) for Neural-tube defect prevention and Folate (B9)
Each entry’s own grades, side by side. A grade says how strong the evidence is for one outcome — it does not rank one entry over the other.
Evidence brief
Folate (B9) for Neural-tube defect prevention
Evidence grade A — Periconceptional; population + RCT
Grade A1 graded outcomerevised Jul 10, 2026
Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.
Compound or practice
Folate (B9)
Prevents neural-tube defects — the one supplement with an unambiguous public-health mandate before and in early pregnancy.
Grade A3 graded outcomesrevised Jul 10, 2026
A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.
Graded in both
Outcomes are matched by name. Two entries can describe the same outcome in different words, so one listed further down may still be graded in the other.
| Outcome | Folate (B9) for Neural-tube defect prevention | Folate (B9) |
|---|---|---|
| Neural-tube defect prevention | Evidence grade ALarge effecthighPericonceptional; population + RCT | Evidence grade ALarge effecthighPericonceptional; population + RCT |
Graded only in Folate (B9) for Neural-tube defect prevention
None — every outcome it grades is graded in both.
Graded only in Folate (B9)
- Homocysteine lowering Moderate effectEvidence grade A
- Cardiovascular events Trivial effectEvidence grade D
What each entry says about the other
- Folate (B9) for Neural-tube defect prevention’s entry · Goes with: Read the full Folate (B9) monograph
Both columns are read from the entries as they stand in this library. A comparison is not advice to take either one, and it is no substitute for a clinician who knows the person.